A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma

Jen Shi Chen, Yee Chao, Yung Jue Bang, Enrique Roca, Hyun C. Chung, Felipe Palazzo, Yeul H. Kim, Scott P. Myrand, Brian P. Mullaney, Li J. Shen, Carlos Linn

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed dose of cisplatin, and the efficacy, toxicity and association of 5,10-methylenetetrahydrofolate reductase (MTHFR) variants with this pemetrexed - cisplatin combination, in patients with unresectable, advanced gastric carcinoma. Patients 18-70 years of age, with stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 or 1 Eastern Cooperative Oncology Group performance status, were included. The cisplatin dose was 75mg/m. In phase I, the initial dose of pemetrexed was 600mg/m, escalated in 100mg/m increments. In phase II, efficacy, including overall response rate, overall survival, as well as toxicity and MTHFR pharmacogenetics were investigated. Phase I enrolled 16 patients; 700mg/m was defined as pemetrexed recommended dose. Thirteen serious adverse events were reported; the most common grade 3/4 toxicities were haematologic (10 of 13, 76.9%). Phase II enrolled 73 patients, 69 qualified for safety and 68 for efficacy analysis; 65 for pharmacogenomic analysis. Overall response rate was 23.5% (14.1%, 35.4%), disease control rate 55.9%, median overall survival 11.8 months (95% confidence interval, 7.2-18.5 months), progression-free survival 4.9 months (95% confidence interval, 2.8-7.1 months), and median response duration 5.4 months. Patients with MTHFR A1298C variants had median overall survival of 6.6 months, significantly shorter than patients with the wild type (median 18.5 months, P=0.001). The pemetrexed - cisplatin combination in patients with advanced gastric cancer generates modest efficacy and a manageable toxicity profile. The reduced overall survival in patients with MTHFR A1298C polymorphism variants deserves further investigation.

Original languageEnglish
Pages (from-to)777-784
Number of pages8
JournalAnti-Cancer Drugs
Volume21
Issue number8
DOIs
Publication statusPublished - 2010 Sep

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Chen, J. S., Chao, Y., Bang, Y. J., Roca, E., Chung, H. C., Palazzo, F., Kim, Y. H., Myrand, S. P., Mullaney, B. P., Shen, L. J., & Linn, C. (2010). A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anti-Cancer Drugs, 21(8), 777-784. https://doi.org/10.1097/CAD.0b013e32833cfbca